We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesMyMD Pharmaceuticals Inc

MyMD Pharmaceuticals Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None USD 0.00(0%)
Last update at 2024-10-23T19:00:25.284737Z
Market Cap
4.62M

Momentum Score

…

MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immunometabolic system and its pro-inflammatory cytokines to treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis. It is also developing Supera-CBD, a synthetic analog of cannabidiol for treating epilepsy, pain, and anxiety/depression. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
1.97
Low
63.90
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
1.33
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.00
ROE
-101.36%
Net Debt
-2.63M
ROCE
-118.71%
Diluted EPS TTM
-9.27

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -15.20M -29.89M -9.49M -3.89M -10.85M
Net income -15.11M -29.88M -10.68M -3.89M -10.85M
Selling general administrative 6.22M 21.46M 5.81M 3.73M 5.67M
Selling and marketing expenses - - 0.02M 0.24M 1.78M
Gross profit 0.00M 0.00M 0.00M 0.48M 0.13M
Reconciled depreciation - 0.00M 0.02M - -
Ebit -15.28M -28.81M -9.49M -3.89M -10.85M
Ebitda -15.20M -28.19M -8.28M -3.81M -10.61M
Depreciation and amortization 0.08M 0.62M 1.21M 0.07M 0.23M
Non operating income net other - - 0.13M - -
Operating income -15.28M -28.81M -9.49M -3.80M -8.56M
Other operating expenses 15.28M 28.20M 8.30M 5.38M 10.22M
Interest expense -0.09M 0.61M 1.19M 0.00M 0.00M
Tax provision 0.00M 0.00M 0.00M - -
Interest income 0.08M 0.01M 0.17M 0.10M 0.14M
Net interest income 0.08M -0.60M -1.19M - -
Extraordinary items - - -5.43M -0.51M -
Income tax expense -0.09M -0.01M 1.19M -0.08M -2.29M
Total revenue 0.00M 0.00M 0.00M 1.58M 1.67M
Total operating expenses 15.28M 28.20M 8.30M 4.28M 8.68M
Cost of revenue 0.00M 0.00M 0.00M 1.10M 1.54M
Total other income expense net 0.09M -1.08M 0.00M -0.08M -2.29M
Discontinued operations - - -5.43M - -
Net income from continuing ops -15.20M -29.89M -12.15M - -
Net income applicable to common shares - -29.89M -8.93M -9.64M -18.07M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 17.86M 17.54M 24.81M 0.68M 10.88M
Intangible assets - - - - 0.17M
Other current assets 0.89M 0.57M 1.11M 0.31M 0.39M
Total liab 5.09M 2.84M 1.17M 5.93M 1.53M
Total stockholder equity 12.77M 14.70M 23.65M -5.26M 9.36M
Other current liab 0.96M 0.35M 0.12M 2.26M 0.87M
Common stock 0.00M 108.31M 102.06M 0.00M 128.92M
Capital stock 0.15M 108.45M 102.21M 0.00M -
Retained earnings -101.98M -93.76M -78.56M -48.67M -119.58M
Other liab - - 0.03M - -
Good will 10.50M 10.50M 10.50M 0.00M -
Other assets 0.00M - - - 0.37M
Cash 2.68M 0.75M 0.56M 0.15M 0.52M
Total current liabilities 4.99M 2.77M 1.04M 2.35M 1.53M
Current deferred revenue 0.27M - - -2.26M -
Net debt -2.63M -0.61M -0.41M 3.98M -0.52M
Short term debt 0.05M 0.07M 0.05M 0.55M -
Short long term debt - - - 0.07M -
Short long term debt total 0.05M 0.14M 0.15M 4.13M -
Other stockholder equity 114.20M 0.14M 0.14M 43.41M 2.12M
Property plant equipment - 0.14M 0.15M 0.53M 0.03M
Total current assets 5.82M 5.40M 12.67M 0.15M 10.31M
Long term investments 1.50M 1.50M 1.50M 0.00M -
Net tangible assets - 4.05M 13.00M -4.09M -1.74M
Short term investments 2.24M 4.09M 11.00M 16.72M 9.16M
Net receivables - - - 1.20M 0.04M
Long term debt - - - 3.53M -
Inventory - - - -1.51M 0.20M
Accounts payable 3.72M 2.36M 0.87M 1.80M 0.66M
Accumulated other comprehensive income -0.00M -0.14M - -0.14M -2.10M
Common stock total equity - - - 171.60M 128.92M
Preferred stock total equity - - - 0.14M -
Retained earnings total equity - - - -137.16M -
Non currrent assets other 0.00M 1.50M 1.50M - 0.37M
Non current assets total 12.05M 12.14M 12.15M 0.53M 0.57M
Capital lease obligations 0.05M 0.14M 0.15M 0.53M -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 6.91M 19.85M -8.76M 18.47M 18.47M
Change to liabilities 0.00M -4.27M 0.15M 0.49M -0.32M
Total cashflows from investing activities - 19.85M -8.76M -3.94M -0.36M
Net borrowings - -1.12M 2.55M 1.93M 5.20M
Total cash from financing activities 5.55M 0.07M 4.68M 6.97M 9.11M
Change to operating activities - -0.91M 0.18M -0.00M 0.02M
Net income -15.20M -29.89M -9.49M -3.89M -10.85M
Change in cash 0.19M 0.41M 0.01M -0.05M 0.24M
Begin period cash flow 0.56M 0.15M 0.13M 0.68M 0.44M
End period cash flow 0.75M 0.56M 0.15M 0.63M 0.68M
Total cash from operating activities -12.27M -19.52M -4.66M -3.07M -8.52M
Issuance of capital stock 5.55M 0.00M 1.98M - -
Depreciation - 0.00M 0.02M 0.07M 0.23M
Other cashflows from investing activities - - -8.76M -3.94M -0.29M
Dividends paid - 0.00M - - -
Change to inventory - - 0.20M 0.01M 0.08M
Change to account receivables - - 0.04M 0.13M 0.63M
Sale purchase of stock - - 1.74M 4.82M 9.11M
Other cashflows from financing activities 6.91M 3.14M 0.95M 0.00M 7.16M
Change to netincome - 14.95M 2.86M 3.58M 10.75M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.07M
Change receivables - - 0.04M - -
Cash flows other operating - - -11.67M - -
Cash and cash equivalents changes - - 17.99M - -
Change in working capital 2.23M -5.18M 0.57M 4.08M -2.86M
Stock based compensation 0.34M - 0.40M 0.40M 0.05M
Other non cash items 0.36M 15.55M 4.23M -3.74M 4.91M
Free cash flow -12.27M -19.52M -4.66M -3.07M -8.59M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

MyMD Pharmaceuticals Inc

MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immunometabolic system and its pro-inflammatory cytokines to treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis. It is also developing Supera-CBD, a synthetic analog of cannabidiol for treating epilepsy, pain, and anxiety/depression. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

855 North Wolfe Street, Baltimore, MD, United States, 21205

856 848 8698

https://www.mymd.com

6

Name Title Year Born
Dr. Christopher C. Chapman Jr., M.D. Pres, Chief Medical Officer & Director 1953
Mr. Paul M. Rivard Esq. Exec. VP of Operations & Gen. Counsel 1971
Dr. Adam Kaplin M.D., Ph.D. Chief Scientific Officer 1967
Mr. Ian Rhodes CPA Interim Chief Financial Officer 1973
Ms. Katherine Whartenby Ph.D. Chief Scientific Advisor & Member of Advisory Board NA
Dr. Christopher C. Chapman Jr., M.D. President, Chief Medical Officer & Director 1953
Dr. Adam Kaplin M.D., Ph.D. Chief Scientific Officer 1968
Dr. Jenna Brager M.S., Ph.D., R.N. Executive Vice President of Drug Development NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…